AstraZeneca and Daiichi Sankyo ... endocrine therapy in the metastatic setting. Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

AstraZeneca PLC (LSE/STO/Nasdaq ... Medicines Agency (EMA), recommending approval of Enhertu as a monotherapy for certain breast cancer patients in the European Union (EU). The recommendation ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2 ... including in 'HER2-ultralow' use, in breast cancer first Stomach cancer has traditionally been a tough nut for researchers ...

for treating breast cancer. "Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial" was originally created and published by Clinical Trials Arena, a GlobalData owned ...

EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Enhertu has already been approved in more than 75 countries, including the EU, for patients with HER2-low metastatic breast cancer based on the DESTINY-Breast04 trial results. As an InvestingPro tip ...